Calcium buffering and protection from excitotoxic cell death by exogenous calbindin-D28k in HEK 293 cells.
Calbindin-D28k (CaBP) is a calcium-binding protein found in specific neuronal populations in the mammalian brain that, as a result of its proposed calcium-buffering action, may protect neurons against potentially harmful increases in intracellular calcium. We have stably transfected HEK 293 cells with recombinant human CaBP in order to determine the influence of this protein upon transient increases in intracellular ionic calcium concentration ([Ca(2+)](i)) induced either by transient transfection of the NR1 and NR2A subunits of the N-methyl-D-aspartate (NMDA) receptor and brief exposure to glutamate, photolysis of the caged calcium compound NP-EGTA, or exposure to the Ca(2+)]-ionophore 4-Br-A23187. The presence of CaBP did not significantly reduce the peak [Ca(2+)](i)stimulated by glutamate activation of NMDA receptors but significantly prolonged the recovery to baseline values. Flash photolysis of NP-EGTA in control cells resulted in an almost instantaneous increase in [Ca(2+)](i)followed by a bi-exponential recovery to baseline values. In cells stably expressing CaBP, the peak [Ca(2+)](i)levels were not statistically different from the controls, however, there was a significant prolongation of the initial portion of the slow recovery phase. In cells exposed to 4-Br-A23187, the presence of CaBP significantly reduced the rate of rise of [Ca(2+)](i), reduced the peak response, slowed the rate of recovery, and reduced the depolarization of mitochondria. In studies of delayed, Ca(2+)]-dependent cell death, CaBP transfected cells exhibited enhanced survival 24h after a 1-h exposure to 200 microM NMDA. However, necrotic cell death observed after the first 6h was not prevented by the presence of CaBP. These results provide direct evidence for a Ca(2+)-buffering effect of CaBP which serves to limit Ca(2+)entry and the depolarization of mitochondria, thereby protecting cells from death mediated most likely by apoptosis.
Rintoul
G L
GL
Department of Physiology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Raymond
L A
LA
Baimbridge
K G
KG
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D002021:Buffers; D064092:Calbindin 1; D064026:Calbindins; D000001:Calcimycin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002478:Cells, Cultured / Q000187:drug effects; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology*; D009498:Neurotoxins / Q000494:pharmacology; D010782:Photolysis; D016194:Receptors, N-Methyl-D-Aspartate / Q000235:genetics / Q000378:metabolism*; D064030:S100 Calcium Binding Protein G / Q000235:genetics / Q000378:metabolism*; D014162:Transfection
D002021:Buffers; C576498:CALB1 protein, human; D064092:Calbindin 1; D064026:Calbindins; C409466:NR1 NMDA receptor; C120997:NR2A NMDA receptor; D009498:Neurotoxins; D016194:Receptors, N-Methyl-D-Aspartate; D064030:S100 Calcium Binding Protein G; C085112:2-nitrophenyl-EGTA; D000001:Calcimycin; D018698:Glutamic Acid; D004533:Egtazic Acid; C033170:4-bromo-A-23187; D002118:Calcium